Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MyomoMYO +5.59%48 Cash Ratio is 1.27 as of Jun. 2026, which is 51% below its 10-year median of 2.61. GuruFocus rates MYO with a GF Score™ of 48/100 and a GF Value™ of $3.15 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Myomo ranks better than 56.24% on this metric.
The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Myomo's Cash Ratio for the quarter that ended in Jun. 2026 was 1.27.
Myomo has a Cash Ratio of 1.27. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Myomo's Cash Ratio or its related term are showing as below:
MYO'
s Cash Ratio Range Over the Past 10 Years
Min: 0.27 Med: 2.61 Max: 12.64
Current: 1.27
During the past 10 years, Myomo's highest Cash Ratio was 12.64. The lowest was 0.27. And the median was 2.61.
MYO's Cash Ratio is ranked better than 56.24% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 0.98
vs MYO: 1.27
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Myomo Cash Ratio Related Terms
Myomo Cash Ratio Historical Data
* Premium members only.
The historical data trend for Myomo's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Myomo's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myomo Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Myomo's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Myomo's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myomo (MYO) has a Cash Ratio of 1.27 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Myomo and its competitors. This is 51% below median its historical median of 2.61. Over the past decade, Myomo's Cash Ratio has ranged from 0.27 to 12.64. According to the industry distribution chart, Myomo ranks #368 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 43.8%.
Is Myomo's Cash Ratio too high?
Myomo's current Cash Ratio of 1.27 is 51% below median its 10-year median of 2.61. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 12.64. The Medical Devices & Instruments industry median Cash Ratio is 0.98. Myomo's value of 1.27 is 29.6% above this industry median. Based on the distribution chart, Myomo ranks #368 out of 841 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Myomo has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myomo's Cash Ratio compare to QTI and NSYS?
According to the Medical Devices & Instruments industry distribution chart, Myomo ranks #368 out of 841 companies for Cash Ratio. This puts Myomo in the upper half of its industry. The industry median Cash Ratio is 0.98. Myomo's value of 1.27 is 29.6% above this benchmark. Historically, Myomo's own Cash Ratio has ranged from 0.27 to 12.64 over the past decade. While the company's 10-year median is 2.61 vs. the industry median of 0.98, Myomo has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Myomo's current Cash Ratio of 1.27 is 29.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Myomo and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myomo's current Cash Ratio is 1.27, which is 51% below median its own 10-year median of 2.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myomo stock overvalued right now?
Based on GuruFocus' analysis, Myomo (MYO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.15, compared to a current price of $1.51 — trading 52.1% below its estimated fair value. The current Cash Ratio is 1.27, which is 51% below median its 10-year median of 2.61 and 29.6% above the Medical Devices & Instruments industry median of 0.98. Myomo's overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Myomo (MYO), the current Cash Ratio is 1.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myomo (MYO) Overvalued in 2026?
Based on GuruFocus' analysis, Myomo stock appears to be undervalued.
The current stock price of $1.51 is trading 52.1% below its estimated GF Value™ of $3.15.
GuruFocus considers Myomo to be Possible Value Trap.
Key valuation signals for MYO:
Cash Ratio: 1.27 (51% below median its 10-year median of 2.61)
GF Value™: $3.15 vs. price of $1.51 (52.1% below fair value)
Industry Position: 29.6% above the Medical Devices & Instruments median (#368 of 841)
No single metric tells the full story. See the MYO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
48GF Score
Get the complete analysis for MYO
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MYO has been successfully added to your 
